Cover Image
市場調查報告書

全球非何杰金氏淋巴瘤治療市場

Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 307327
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
全球非何杰金氏淋巴瘤治療市場 Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018
出版日期: 2014年06月30日 內容資訊: 英文 91 Pages
簡介

全球非何杰金氏淋巴瘤治療市場,預計從2013年到2018年,以7.03%的年複合成長率擴大。

本報告提供全球非何杰金氏淋巴瘤治療市場現狀與未來預測、各終端用戶、各地區的趨勢、市場成長因素與課題、主要供應商的簡介等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
    • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 罹患率和發病率

第8章 各治療類型的市場區隔

  • 化療
  • 標靶治療

第9章 產品研發線

第10章 地理區分

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析

  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline plc

第20章 相關報告

目錄
Product Code: IRTNTR3709

About Non-Hodgkin Lymphoma (NHL) and its Diagnostic Procedures

Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests.

TechNavio's analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.

TechNavio's report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bristol Myers Squibb Co.
  • Celgene Corp.
  • Eli Lilly and Co.
  • F. Hoffman La-Roche Ltd.
  • GlaxoSmithKline plc

Other Prominent Vendors

  • Accredo Health Group Inc.
  • Baxter International Inc.
  • Bayer AG
  • Cephalon Inc.
  • Eisai Pharmaceuticals Inc.
  • Genelabs Technologies Inc.
  • Hospira Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Millenium Pharmaceuticals Inc.
  • Pacira Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Inc.

Key Market Driver

  • Availability of Biosimilars at a Reduced Price.

For a full, detailed list, view our report.

Key Market Challenge

  • High Cost of NHL Drugs.

For a full, detailed list, view our report.

Key Market Trend

  • Dominance of NHL Market by Biologics.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

  • 08.1.1. Chemotherapy
  • 08.1.2. Targeted Therapy

09. Pipeline Portfolio

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Bristol-Myers Squibb Co.
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Product Segmentation
    • 19.1.4. Sales by Geography
    • 19.1.5. Business Strategy
    • 19.1.6. Key Information
    • 19.1.7. SWOT Analysis
    • 19.1.8. Strengths
    • 19.1.9. Weaknesses
    • 19.1.10. Opportunities
    • 19.1.11. Threats
  • 19.2. Celgene Corp.
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Strategy
    • 19.2.4. Business Segmentation by Revenue 2011-2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Key Developments
    • 19.2.7. SWOT Analysis
    • 19.2.8. Strengths
    • 19.2.9. Weaknesses
    • 19.2.10. Opportunities
    • 19.2.11. Threats
  • 19.3. Eli Lilly and Co.
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis
    • 19.3.9. Strengths
    • 19.3.10. Weaknesses
    • 19.3.11. Opportunities
    • 19.3.12. Threats
  • 19.4. F. Hoffmann La Roche Ltd.
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Sales by Geography
    • 19.4.6. Business Strategy
    • 19.4.7. Key Information
    • 19.4.8. SWOT Analysis
    • 19.4.9. Strengths
    • 19.4.10. Weaknesses
    • 19.4.11. Opportunities
    • 19.4.12. Threats
  • 19.5. GlaxoSmithKline plc
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Sales by Geography
    • 19.5.6. Pipeline Products
    • 19.5.7. Business Strategy
    • 19.5.8. Key Information
    • 19.5.9. SWOT Analysis
    • 19.5.10. Strengths
    • 19.5.11. Weaknesses
    • 19.5.12. Opportunities
    • 19.5.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Non-Hodgkin Lymphoma therapeutics market (in US$ billions)
  • Exhibit 3: Global Non-Hodgkin Lymphoma Therapeutics Market by Type of Therapy
  • Exhibit 4: Pipeline Portfolio of Global Non-Hodgkin Lymphoma Therapeutics Market
  • Exhibit 5: Global NHL Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
  • Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
  • Exhibit 8: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 9: Celgene Corp.: Sales by Geography 2013
  • Exhibit 10: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 11: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 12: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 17: GlaxoSmithKline Plc: Business Segmentation 2013
  • Exhibit 18: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)
  • Exhibit 19: GlaxoSmithKline Plc: Sales by Geography 2013
  • Exhibit 20: GlaxoSmithKline plc: Pipeline Products 2013
Back to Top